DongKoo Bio & Pharma Co. Ltd. Cash Flow Conversion Efficiency
DongKoo Bio & Pharma Co. Ltd. cash flow conversion efficiency. Based on the latest financial reports, DongKoo Bio & Pharma Co. Ltd. (006620) has a cash flow conversion efficiency ratio of 0.031x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.46 Billion ≈ $3.02 Million USD) by net assets (₩142.58 Billion ≈ $96.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DongKoo Bio & Pharma Co. Ltd. (2015–2025)
Cash flow conversion efficiency of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. This chart illustrates how DongKoo Bio & Pharma Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View DongKoo Bio & Pharma Co. Ltd. (006620) share price today for real-time trading data and today's change.
DongKoo Bio & Pharma Co. Ltd. Cash Flow Conversion Ratio Explained
DongKoo Bio & Pharma Co. Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DongKoo Bio & Pharma Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKoo Bio & Pharma Co. Ltd. ranked by their cash flow conversion efficiency. Also see DongKoo Bio & Pharma Co. Ltd. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rackla Metals Inc
V:RAK
|
-0.294x |
|
Nextplat Corp
NASDAQ:NXPL
|
0.066x |
|
Kidoz Inc
V:KIDZ
|
0.061x |
|
Slj Global Tbk
JK:SULI
|
-0.018x |
|
Bull Will Co Ltd
TWO:6259
|
-0.004x |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
-0.063x |
|
Protasco Bhd
KLSE:5070
|
0.007x |
|
Agroton Public Ltd.
WAR:AGT
|
-0.142x |
Annual Cash Flow Conversion Efficiency for DongKoo Bio & Pharma Co. Ltd. (2015–2025)
The table below shows the annual cash flow conversion efficiency of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. Review DongKoo Bio & Pharma Co. Ltd. (006620) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩152.16 Billion ≈ $103.12 Million |
₩-4.29 Billion ≈ $-2.91 Million |
-0.028x | -117.11% |
| 2024-12-31 | ₩105.33 Billion ≈ $71.38 Million |
₩17.34 Billion ≈ $11.75 Million |
0.165x | +407.23% |
| 2023-12-31 | ₩110.44 Billion ≈ $74.85 Million |
₩3.59 Billion ≈ $2.43 Million |
0.032x | -80.29% |
| 2022-12-31 | ₩102.11 Billion ≈ $69.20 Million |
₩16.82 Billion ≈ $11.40 Million |
0.165x | -7.88% |
| 2021-12-31 | ₩100.12 Billion ≈ $67.85 Million |
₩17.90 Billion ≈ $12.13 Million |
0.179x | +126.00% |
| 2020-12-31 | ₩94.65 Billion ≈ $64.14 Million |
₩7.49 Billion ≈ $5.08 Million |
0.079x | -33.16% |
| 2019-12-31 | ₩85.65 Billion ≈ $58.05 Million |
₩10.14 Billion ≈ $6.87 Million |
0.118x | +1178.70% |
| 2018-12-31 | ₩72.10 Billion ≈ $48.86 Million |
₩-791.20 Million ≈ $-536.19K |
-0.011x | -104.36% |
| 2017-12-31 | ₩37.74 Billion ≈ $25.58 Million |
₩9.51 Billion ≈ $6.44 Million |
0.252x | -55.89% |
| 2016-12-31 | ₩22.05 Billion ≈ $14.94 Million |
₩12.59 Billion ≈ $8.53 Million |
0.571x | -79.00% |
| 2015-12-31 | ₩2.55 Billion ≈ $1.73 Million |
₩6.93 Billion ≈ $4.70 Million |
2.719x | -- |
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more